Dabigatran and Anagrelide: Interaction Details
- Anagrelide
- Agrylin
- Dabigatran
- Pradaxa
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Dabigatran and Anagrelide interaction:
What Happens When You Take Dabigatran With Anagrelide
What can happen when they are taken together (rated Major)
Increased risk of bleeding
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Serious bleeding, occasionally fatal, may occur with dabigatran etexilate, and taking agents at the same time raises this risk further. Any sign or symptom suggesting blood loss (for example, or a fall in HB and/or HCT) should be assessed without delay, and dabigatran etexilate should be stopped in patients who have active pathological bleeding.
In patients undergoing spinal puncture or receiving neuraxial anesthesia, may also heighten the risk of spinal or epidural hematomas, which can lead to permanent or long-term paralysis.1 In a study of elderly patients who had received a coronary artery stent, combining a DOAC (dabigatran among them) with prescription antiplatelet therapy (mostly clopidogrel) led to a higher risk of major than antiplatelet therapy alone.4 By contrast, another study of patients with atrial fibrillation or VTE found that adding antiplatelet therapy (mostly low-dose aspirin) to a DOAC did not significantly change the incidence of major bleeding or clinically relevant non-major bleeding relative to DOAC therapy alone.3
The Dabigatran and Anagrelide Interaction, Explained
Anagrelide (Agrylin) lowers your count, and at higher doses it can also make platelets less sticky. Dabigatran (Pradaxa) is a that helps prevent clots. Because both affect how your blood clots, taking them together may raise your risk of bleeding. This concern is mostly theoretical, based on how the drugs work rather than on direct studies of this pair.
Watch for unusual bruising, bleeding gums, nosebleeds that won't stop, blood in your urine or stool, black stools, or feeling dizzy or weak. Keep taking your medicines as prescribed, and tell your pharmacist or doctor about any of these signs. Your care team can watch you closely and keep you safe.
Mechanism: , impairment of hemostasis. Anagrelide reduces count (megakaryocyte maturation) and has PDE3-mediated activity. Dabigatran is a direct thrombin . No meaningful PK interaction expected.
Direction/evidence: Increased bleeding risk. Evidence is theoretical, extrapolated from DOAC plus antiplatelet data (mixed results: increased major with mainly clopidogrel post-stent; no significant change with low-dose aspirin in VTE/AF). Onset unspecified. Severity: major.
- Monitor for bleeding; evaluate promptly any drop in Hb/Hct or .
- Discontinue dabigatran in active pathological bleeding.
- Increased risk of epidural/spinal hematoma with neuraxial anesthesia or spinal puncture.
See the 4 references behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Dabigatran and Anagrelide Interact
The likely mechanism
effects on hemostasis
How to Manage the Dabigatran and Anagrelide Interaction
Your care team can manage this combination by watching you more closely for bleeding. If you have signs of blood loss, they may check your blood counts and blood pressure and decide whether changes are needed.
- Keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise.
- Report unusual bruising, bleeding, black or bloody stools, or dizziness right away.
- Before any spinal or epidural procedure (such as a spinal tap or epidural anesthesia), tell the doctor you take both medicines.
- Ask your pharmacist before adding other products that can increase bleeding, such as aspirin or ibuprofen.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Dabigatran or Anagrelide need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
3 reports from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Direct oral anticoagulant plus antiplatelet therapy: prescribing practices and bleeding outcomes
In a retrospective study, combined use of a direct oral (DOAC) with therapy (APT; n=78), compared with DOAC therapy alone (n=329), did not significantly change the incidence of major bleeding (1.3% vs 1.2%) or clinically relevant non-major bleeding (10.2% vs 6.4%) across 6 months of treatment. The study population consisted mainly of Caucasian men, with a mean age of 63.7 years.
Compared with patients given DOAC monotherapy, those on concurrent APT had a significantly higher mean body mass index (30.7 vs 28.4) and mean CHA2DS2-VASc score (4.28 vs 3.85), and were more likely to have diabetes (26.9% vs 17.3%). The DOACs, prescribed for VTE treatment or atrial fibrillation, were apixaban (58.5%), rivaroxaban (38.1%), and dabigatran (3.4%).
Single antiplatelet therapy was used in 94.9% (74 patients), and the most frequent regimen was aspirin 81 mg once daily (69 patients). The remaining APT regimens were aspirin 81 mg twice daily (3 patients), aspirin 325 mg daily (1 patient), clopidogrel 75 mg daily (1 patient), and dual APT consisting of aspirin 81 mg and clopidogrel 75 mg daily (4 patients).3
-
Report 2 · Study title
Direct oral anticoagulant and antiplatelet combination therapy: hemorrhagic events in coronary artery stent recipients
A retrospective study of patients aged 65 years or older who underwent coronary artery stent placement (N=70,900) found that, over the 12 months after stenting, of a direct oral (DOAC; dabigatran or rivaroxaban) with prescription therapy (mostly clopidogrel) significantly raised the risk of major events relative to antiplatelet therapy alone (HR, 2.36; 95% CI, 1.91 to 2.93); this risk was comparable to that seen with concurrent warfarin and antiplatelets (HR, 2; 95% CI, 1.83 to 2.18). After stratification by index atrial fibrillation (AF) status, concurrent DOAC and antiplatelet therapy was likewise associated with a significantly increased risk of major hemorrhagic events in both the AF group (HR, 1.94; 95% CI, 1.48 to 2.54; n=10,238) and the non-AF group (HR, 3.09; 95% CI, 2.15 to 4.46; n=60,662).
Hemorrhages occurring within the first 30 days after stenting were classified as periprocedural morbidity and were excluded. The mean observation period was 11.5 months, totaling 24.470,270 person-days of exposure; of these, antiplatelet therapy alone made up 73.8%, antiplatelets plus DOACs 0.6%, and antiplatelets plus warfarin 4.7%.4
-
Report 3 · Study title
Prescribing information: PRADAXA oral capsules, dabigatran etexilate oral capsules
In a drug interaction study, giving dabigatran 110 mg twice daily together with ticagrelor 90 mg twice daily raised dabigatran by 26% and by 29%, whereas giving it together with a ticagrelor 180 mg loading dose raised these values by 49% and 65%, respectively. When the ticagrelor 180 mg loading dose was instead administered 2 hours after dabigatran, however, dabigatran AUC and Cmax rose by only 27% and 24%, respectively.1
Dabigatran and Anagrelide: Common Questions
How serious is the Dabigatran and Anagrelide interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Dabigatran and Anagrelide interaction managed?
Your care team can manage this combination by watching you more closely for bleeding. If you have signs of blood loss, they may check your blood counts and blood pressure and decide whether changes are needed. Keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise. Report unusual bruising, bleeding, black or bloody stools, or dizziness right away. Before any sp… Management is individual — always follow your own care team's guidance.
Who is at higher risk from the Dabigatran and Anagrelide interaction?
The interaction record names this group as more likely to be affected:
- Older adults
If this describes you, tell your pharmacist or prescriber.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
Ask About the Dabigatran and Anagrelide Interaction
Ask in your own words about taking Dabigatran and Anagrelide together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (4)
- Product Information: PRADAXA(R) oral capsules, dabigatran etexilate oral capsules. Boehringer Ingelheim Pharmaceuticals Inc (per FDA), Ridgefield, CT, 2023. DailyMed
- Product Information: PRADAXA(R) oral pellets, dabigatran etexilate oral pellets. Boehringer Ingelheim Pharmaceuticals Inc (per FDA), Ridgefield, CT, 2023. DailyMed
- Tinkham TT, Vazquez SR, Jones AE, et al: Direct oral anticoagulant plus antiplatelet therapy: prescribing practices and bleeding outcomes. J Thromb Thrombolysis 2020; 49(3):492-496. PubMed
- Bekelis K, Chang CH, Malenka D, et al: Direct oral anticoagulant and antiplatelet combination therapy: hemorrhagic events in coronary artery stent recipients. J Clin Neurosci 2018; 50:24-29. PubMed
Other Serious Interactions of Dabigatran and Anagrelide
Also serious with Anagrelide
- AbrocitinibContraindicated
- DronedaroneContraindicated
- LevoketoconazoleContraindicated
- PimozideContraindicated
Also serious with Dabigatran
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Anagrelide
- Activated CharcoalMajor
- PiracetamMajor
- Vitamin EModerate
- SeleniumModerate
- GingerModerate
- TurmericModerate
- CaffeineModerate
- Green TeaModerate
- + 263 more
With Dabigatran
- St. John's WortMajor
- Activated CharcoalMajor
- PiracetamMajor
- Vitamin EModerate
- SeleniumModerate
- GingerModerate
- TurmericModerate
- CaffeineModerate
- + 233 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.